# EDGAR Filing Document

**Accession Number:** 0001630212
**File Stem:** 0001213900-23-018007
**Filing Date:** 2023-3
**Character Count:** 4720
**Document Hash:** 1ca48487020b92524c6e9a5d2ee0b3ab
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-018007.hdr.sgml**: 20230307

**ACCESSION NUMBER**: 0001213900-23-018007

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230109

**FILED AS OF DATE**: 20230307

**DATE AS OF CHANGE**: 20230307

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Felix Lourdes
- **CENTRAL INDEX KEY:** 0001569735

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38728
- **FILM NUMBER:** 23711547

**MAIL ADDRESS:**
- **STREET 1:** 15 CALLE VERANO
- **CITY:** RANCHO SANTA MARGARITA
- **STATE:** CA
- **ZIP:** 92688
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Avalon GloboCare Corp.
- **CENTRAL INDEX KEY:** 0001630212
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 471685128
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 4400 ROUTE 9
- **STREET 2:** SUITE 3100
- **CITY:** FREEHOLD
- **STATE:** NJ
- **ZIP:** 07728
- **BUSINESS PHONE:** 732-780-4400

**MAIL ADDRESS:**
- **STREET 1:** 4400 ROUTE 9
- **STREET 2:** SUITE 3100
- **CITY:** FREEHOLD
- **STATE:** NJ
- **ZIP:** 07728

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Avalon Globocare Corp.
- **DATE OF NAME CHANGE:** 20161018

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GLOBAL TECHNOLOGIES CORP
- **DATE OF NAME CHANGE:** 20150108

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Felix Lourdes<br><sub>(Last) (First) (Middle)</sub><br>C/O AVALON GLOBOCARE CORP.<br>4400 ROUTE 9 SOUTH, SUITE 3100<br><sub>(Street)</sub><br>FREEHOLD, NJ 07728<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Avalon GloboCare Corp. [ ALBT ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-01-09 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [ ] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option<sup>(1)</sup> | 2023-01-09 | 2028-01-09 | Common Stock, $0.0001 par value per share | 7803 | $4.01 | D |  |

---

### Footnotes:

(1) For 2023, the Company granted Ms. Felix options to acquire 7,803 shares of common stock at an exercise price of $4.01 for a term of five years with 1,803 options vesting during the first calendar quarter and the balance vesting at the rate of 2,000 options at the beginning of every quarter during 2023.

**Signature:** /s/ Lourdes Felix  
**Date:** 2023-03-07

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**